Please ensure Javascript is enabled for purposes of website accessibility

Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

By Joe Tenebruso - Updated Jan 19, 2021 at 12:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are excited about the biotech's clinical trial results.

What happened

Shares of Aclaris Therapeutics (ACRS 0.67%) surged on Tuesday, following the release of promising data regarding its experimental treatment for rheumatoid arthritis. 

As of 12:20 a.m. EST today, the pharmaceutical company's stock price was up 212%.

So what 

Aclaris Therapeutics announced preliminary results from a phase 2a clinical trial of ATI-450, an investigational oral MK2 inhibitor, in patients with moderate to severe rheumatoid arthritis. ATI-450 reportedly demonstrated a "marked and sustained reduction" in disease-activity scores in the placebo-controlled study. It was also shown to be generally well tolerated, with no serious adverse events reported during the trial.

A person is pointing to an upwardly sloping line.

Aclaris Therapeutics stock soared on Tuesday. Image source: Getty Images.

Dr. David Gordon, Aclaris chief medical officer, said in a press release, "We believe these data support our hypothesis that MK2 inhibition is an important novel target for the treatment of immuno-inflammatory diseases, such as rheumatoid arthritis, and we look forward to progressing ATI-450 to phase 2b." 

Now what

Aclaris intends to submit a comprehensive analysis of its phase 2a study for peer review in a scientific journal in the coming weeks. Doctors are hopeful that ATI-450 could represent a new way to combat inflammatory diseases.

"Despite recent advances, rheumatoid arthritis continues to be a significant burden for large numbers of patients," said Dr. Stanley Cohen, co-director of the Division of Rheumatology at Presbyterian Hospital in Dallas. "These results are very encouraging and support further development of ATI-450 to treat rheumatoid arthritis with a new mechanism of action."

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aclaris Therapeutics, Inc. Stock Quote
Aclaris Therapeutics, Inc.
ACRS
$12.11 (0.67%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.